Safety Assessment

From complete IND-enabling programs to stand-alone assessments, our Safety Assessment team provides a full range of in vivo and in vitro testing services and regulatory support to comply with worldwide regulatory restrictions for the nonclinical development of pharmaceuticals, medical devices and animal health products as well as chemicals, agrochemicals, and biocides. Our scientific and regulatory staff work with clients to develop and execute individual studies or customized testing programs to ensure that drug safety and efficacy assessments are conducted in the most efficient manner.

Talk to an Expert

 


Pathologist looking at computer

Simplifying Your Pathology Workflow

As part of an overall effort to streamline your development programs and deliver faster results, Charles River is implementing state-of-the-art technologies that introduce greater efficiencies at every stage of the process. The latest advance at Charles River is a fully GLP compliant digital pathology workflow that supports pathology peer review globally across our sites.

Learn More


Photo of nurse with patient.

What's a week worth to your Patients?

As part of our commitment to accelerate your drug development program, we’ve condensed our reporting timeline to nine weeks for GLP-IND-enabling studies (up to three months in duration without peer review, 11 weeks for studies with peer review). Give your therapy the best chance to get to patients first. Choose a partner who delivers your safety data faster.

Accelerate your Therapy


79621595_xl.jpg

IND-Enabling Studies Toolbox

Planning for your IND-enabling studies requires the right partner to support your program, preparing the proper test articles, and planning your submissions. Make sure you choose a partner that can quickly mitigate any risks, deliver reports quickly, and offer actionable insights to submit your investigational new drug application on time.

Get the tools